

PRIOR AUTHORIZATION POLICY

POLICY: Pulmonary Arterial Hypertension – Winrevair Prior Authorization Policy

- Winrevair™ (sotaterept-csrk subcutaneous injection – Merck)

REVIEW DATE: 04/10/2024

OVERVIEW

Winrevair, an activin signaling inhibitor, is indicated for the treatment of **pulmonary arterial hypertension (PAH)** [World Health Organization {WHO} Group 1] in adults to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.

Disease Overview

PAH is a serious but rare condition with an estimated prevalence of 10.6 cases per 1 million adults in the US.² It is classified within WHO Group 1 pulmonary hypertension among the five different groups that are recognized. In this progressive disorder, the small arteries in the lungs become narrowed, restricted, or blocked. This causes the heart to work harder to pump blood, leading to activity impairment. Although the mean age of diagnosis is between 36 and 50 years, patients of any age may be affected. PAH is defined as a mean pulmonary artery pressure (mPAP) > 20 mmHg (at rest) with a pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg and a pulmonary vascular resistance > 2 Wood units measured by cardiac catheterization.^{3,4} Despite the introduction of many PAH-specific therapies, mortality associated with PAH remains high. When stratified into intermediate and high risk PAH, the 3-year mortality rate was reported as 18% to 20% for intermediate risk and 28% to 55% for high risk PAH.⁵

Guidelines

Various guidelines for PAH are available; however, none address Winrevair yet.

- In 2022, the European Society of Cardiology and the European Respiratory Society (ESC/ERS) updated guidelines on the diagnosis and management of PAH in adults.³ The treatment algorithm for PAH has been simplified, with a clear focus on individual risk assessment, cardiopulmonary comorbidities, and treatment goals. Generally, combination therapy with a phosphodiesterase type 5 inhibitor (PDE5i) and endothelin receptor antagonist (ERA) are recommended as initial therapy in patients considered low risk. If low-risk status is not achieved within 3 to 6 months, the addition of a prostacyclin analogue is recommended. Combination therapy including an intravenous (IV) prostacyclin analogue is recommended as initial therapy in patients considered high-risk.
- The CHEST guidelines (2019) use the patient's functional class (FC) to determine disease severity instead of the comprehensive risk assessment.⁶ The guidelines recommend initiating combination oral therapy with an ERA and a PDE5i for patients with mild or moderate disease (FC II or III) or IV prostacyclin therapy for patients with severe disease (FC III with rapid disease progression or FC IV). Patients who remain symptomatic despite initial treatment should be treated with a second or third agent. Those who fail to improve despite maximal medical therapy should be considered for lung transplant evaluation.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Winrevair. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with these products as well as the monitoring required for adverse events and

long-term efficacy, approval requires these agents to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Documentation: Documentation is required for initiation of therapy as noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes and catheterization laboratory reports. For a patient case in which the documentation requirement of the right heart catheterization upon Prior Authorization coverage review for a different medication indicated for WHO Group 1 PAH has been previously provided, the documentation requirement in this *Pulmonary Arterial Hypertension – Winrevair Prior Authorization Policy* is considered to be met.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Winrevair is recommended in those who meet the following criteria:

FDA-Approved Indication

1. Pulmonary Arterial Hypertension (PAH) [World Health Organization {WHO} Group 1].

Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii, iii, iv and v):

i. Patients is ≥ 18 years of age; AND

ii. Patient meets the following (a and b):

a) The patient has had a right heart catheterization **[documentation required]** (see documentation section above); AND

b) The results of the right heart catheterization confirmed the diagnosis of WHO Group 1 PAH; AND

iii. Patient is in Functional Class II or III; AND

iv. Patient meets ONE of the following (a or b):

a) Patient is currently receiving at least two other PAH therapies from the following different pharmacologic categories each for ≥ 60 days: phosphodiesterase type 5 inhibitors (PDE5i), endothelin receptor antagonists (ERAs), soluble guanylate cyclase stimulator (sGCs), and prostacyclins; OR

b) Patient is currently receiving at least one other PAH therapy for ≥ 60 days and is intolerant to combination therapy with a phosphodiesterase type 5 inhibitors (PDE5i), endothelin receptor antagonists (ERAs), soluble guanylate cyclase stimulator (sGCs), or prostacyclin; AND

Note: Examples of PDE5i include sildenafil and tadalafil. Examples of ERAs include bosentan, ambrisentan, and Opsumit (macitentan tablets). Example of sGCs includes Adempas (riociguat tablets). Examples of prostacyclins include Tyvaso (treprostinil inhalation solution), Tyvaso DPI (treprostinil inhalation solution), Ventavis (iloprost inhalation solution), Orenitram (treprostinil tablets), Upravi (selexipag tablets), treprostinil injection and epoprostenol injection.

v. The medication is prescribed by or in consultation with a cardiologist or a pulmonologist.

B) Patient is Currently Receiving Winrevair. Approve for 1 year if the patient meets BOTH of the following (i and ii):

i. Patient meets BOTH of the following (a and b):

a) Patient has had a right heart catheterization; AND

Note: This refers to prior to starting therapy with a medication for WHO Group 1 PAH.

- b) Results of the right heart catheterization confirmed the diagnosis of WHO Group 1 PAH;
AND
- ii. The medication is prescribed by or in consultation with a cardiologist or a pulmonologist.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Winrevair is recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Winrevair® subcutaneous injection [prescribing information]. Rahway, NJ: Merck; March 2024.
2. Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension. A review. *JAMA*. 2022;327(14):1379-1391.
3. Humbert M, Kovacs G, Hoeper MM, et al, for the ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022;43(38):3618-3731.
4. Maron B. Revised definition of pulmonary hypertension and approach to management: a clinical primer. *J Am Heart Assoc*. 2023 April 7. [epub ahead of print].
5. Chang KY, Duval S, Badesch DB, et al. PHAR Investigators Mortality in Pulmonary Arterial Hypertension in the modern era: early insights from the Pulmonary Hypertension Association Registry. *J Am Heart Assoc*. 2022 May 3;11(9):e024969. doi: 10.1161/JAHA.121.024969.
6. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults. Update of the CHEST guideline and Expert Panel Report. *CHEST*. 2019;155(3):565-586.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	-	04/10/2024